Market revenue in 2023 | USD 652.5 million |
Market revenue in 2030 | USD 1,458.4 million |
Growth rate | 12.2% (CAGR from 2023 to 2030) |
Largest segment | Sipuleucel-t (provenge) |
Fastest growing segment | Other Vector Type |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Sipuleucel-T (Provenge), CreaVax, Other Vector Type |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dendritic cell cancer vaccine market will help companies and investors design strategic landscapes.
sipuleucel-t (provenge) was the largest segment with a revenue share of 84.4% in 2023. Horizon Databook has segmented the Global dendritic cell cancer vaccine market based on sipuleucel-t (provenge), creavax, other vector type covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of global-level data and insights on the Global dendritic cell cancer vaccine market , including forecasts for subscribers. This global databook contains high-level insights into Global dendritic cell cancer vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account